227 related articles for article (PubMed ID: 21416259)
1. Heart failure pharmacogenetics: past, present, and future.
Davis HM; Johnson JA
Curr Cardiol Rep; 2011 Jun; 13(3):175-84. PubMed ID: 21416259
[TBL] [Abstract][Full Text] [Related]
2. State of play of pharmacogenetics and personalized medicine in heart failure.
Parry HM; Doney AS; Palmer CN; Lang CC
Cardiovasc Ther; 2013 Dec; 31(6):315-22. PubMed ID: 23480579
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic management of heart failure: neurohormonal agents.
Moser DK
Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics in chronic heart failure: new developments and current challenges.
Talameh JA; Lanfear DE
Curr Heart Fail Rep; 2012 Mar; 9(1):23-32. PubMed ID: 22135185
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
McNamara DM; Holubkov R; Janosko K; Palmer A; Wang JJ; MacGowan GA; Murali S; Rosenblum WD; London B; Feldman AM
Circulation; 2001 Mar; 103(12):1644-8. PubMed ID: 11273991
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics in heart failure: promises and challenges.
de Boer RA; van der Harst P; van Veldhuisen DJ; van den Berg MP
Expert Opin Pharmacother; 2009 Aug; 10(11):1713-25. PubMed ID: 19558337
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function.
McNamara DM
Congest Heart Fail; 2004; 10(6):302-8. PubMed ID: 15591845
[TBL] [Abstract][Full Text] [Related]
9. Beta-blocker pharmacogenetics in heart failure.
Shin J; Johnson JA
Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of drug response in heart failure.
Lowes BD; Buttrick PM
Curr Cardiol Rep; 2008 May; 10(3):176-81. PubMed ID: 18489860
[TBL] [Abstract][Full Text] [Related]
11. Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.
Talameh JA; McLeod HL; Adams KF; Patterson JH
J Card Fail; 2012 Apr; 18(4):338-49. PubMed ID: 22464776
[TBL] [Abstract][Full Text] [Related]
12. Current treatment and future directions in heart failure.
Wells G; Little WC
Curr Opin Pharmacol; 2002 Apr; 2(2):148-53. PubMed ID: 11950625
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin gene polymorphisms and neurohormonal inhibition.
Pauly DF
Heart Fail Clin; 2010 Jan; 6(1):25-6. PubMed ID: 19945057
[TBL] [Abstract][Full Text] [Related]
14. Progress toward genetic tailoring of heart failure therapy.
Lillvis JH; Lanfear DE
Curr Opin Mol Ther; 2010 Jun; 12(3):294-304. PubMed ID: 20521218
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of heart failure.
Lymperopoulos A; French F
Methods Mol Biol; 2014; 1175():245-57. PubMed ID: 25150872
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of antihypertensive treatment.
Arnett DK; Claas SA; Glasser SP
Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics for neurohormonal intervention in heart failure.
McNamara DM
Heart Fail Clin; 2005 Apr; 1(1):141-50. PubMed ID: 17386840
[No Abstract] [Full Text] [Related]
18. Genomic variation and neurohormonal intervention in heart failure.
McNamara DM
Heart Fail Clin; 2010 Jan; 6(1):35-43. PubMed ID: 19945059
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
McNamara DM; Holubkov R; Postava L; Janosko K; MacGowan GA; Mathier M; Murali S; Feldman AM; London B
J Am Coll Cardiol; 2004 Nov; 44(10):2019-26. PubMed ID: 15542286
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.
Beitelshees AL; Zineh I
Heart Fail Rev; 2010 May; 15(3):209-17. PubMed ID: 18351457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
